Predicted to have magnesium ion binding activity and microtubule-severing ATPase activity. Predicted to be involved in several processes, including cellular response to ionizing radiation; osteoblast proliferation; and regulation of double-strand break repair via homologous recombination. Predicted to localize to nuclear chromosome and perinuclear region of cytoplasm. Orthologous to human FIGNL1 (fidgetin like 1); INTERACTS WITH 1-naphthyl isothiocyanate; 3,3',4,4',5-pentachlorobiphenyl; acetamide.
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of FIGNL1 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of FIGNL1 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of FIGNL1 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of FIGNL1 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of FIGNL1 mRNA
[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of FIGNL1 mRNA, [pirinixic acid co-treated with PPARA] results in increased expression of FIGNL1 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of FIGNL1 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of FIGNL1 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin